<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006909.pub2" GROUP_ID="EYES" ID="686306060711515314" MERGED_FROM="" MODIFIED="2011-12-12 19:24:56 +0100" MODIFIED_BY="Anupa Shah" REVIEW_NO="NOLO01" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2011-12-12 19:24:56 +0100" MODIFIED_BY="Anupa Shah">
<TITLE>Interventions for prevention of giant retinal tear in the fellow eye</TITLE>
<CONTACT MODIFIED="2011-12-12 19:24:56 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="C7D83F4982E26AA201BBAD6F8E08ED20" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Noemi</FIRST_NAME><LAST_NAME>Lois</LAST_NAME><POSITION>Consultant Ophthalmologist</POSITION><EMAIL_1>noemilois@aol.com</EMAIL_1><ADDRESS><DEPARTMENT>Ophthalmology Department</DEPARTMENT><ORGANISATION>Grampian University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Foresterhill</ADDRESS_1><CITY>Aberdeen</CITY><ZIP>AB25 2ZN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1224 553217</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-12-12 19:24:56 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="ADE6527F82E26AA20178986B21D5D83E" ROLE="AUTHOR"><FIRST_NAME>Ghee Soon</FIRST_NAME><LAST_NAME>Ang</LAST_NAME><POSITION>Specialist Registrar</POSITION><EMAIL_1>gsang1@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Ophthalmology</DEPARTMENT><ORGANISATION>Aberdeen Royal Infirmary</ORGANISATION><ADDRESS_1>Foresterhill</ADDRESS_1><CITY>Aberdeen</CITY><ZIP>AB25 2ZN</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="C7DF000B82E26AA201BBAD6FF8E3692F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Townend</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>j.townend@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>School of Medicine, Polwarth Building</ADDRESS_1><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="C7D83F4982E26AA201BBAD6F8E08ED20" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Noemi</FIRST_NAME><LAST_NAME>Lois</LAST_NAME><POSITION>Consultant Ophthalmologist</POSITION><EMAIL_1>noemilois@aol.com</EMAIL_1><ADDRESS><DEPARTMENT>Ophthalmology Department</DEPARTMENT><ORGANISATION>Grampian University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Foresterhill</ADDRESS_1><CITY>Aberdeen</CITY><ZIP>AB25 2ZN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1224 553217</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-12-12 17:53:49 +0000" MODIFIED_BY="Anupa Shah">
<UP_TO_DATE>
<DATE DAY="6" MONTH="12" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="12" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="1" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2011-12-12 18:16:46 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-12-12 18:14:54 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="12" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Issue 2 2012: Electronic searches were updated but no new studies were identified for inclusion in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-12-12 18:16:46 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="12" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Issue 2 2012: Minor editing done to review text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-12 17:53:59 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-12-12 17:53:59 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="4" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Issue 1, 2010: updated searches yielded no RCTs. One retrospective study Al-Khairi 2008 (which was identified from the original search) has been added to the discussion section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-27 14:25:52 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="6" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-12-12 18:21:25 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY MODIFIED="2011-12-12 18:21:14 +0000" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2008-11-27 14:35:10 +0000" MODIFIED_BY="Anupa Shah">Interventions for prevention of giant retinal tear in the fellow eye</TITLE>
<SUMMARY_BODY MODIFIED="2011-12-12 18:21:14 +0000" MODIFIED_BY="Anupa Shah">
<P>A giant retinal tear is a full-thickness retinal break that extends for 90 degrees or more around the circumference of the retina, in the presence of posterior vitreous detachment (when the vitreous comes away from the retina). Giant retinal tears cause visual loss as a result of the associated retinal detachment. They can be difficult to treat due to the large area of retinal involvement and the high risk of re-detachment following vitreoretinal surgery, often related to the development of proliferative vitreoretinopathy (a scarring process that can happen on the inner or outer surface of the retina and in the vitreous cavity after retinal detachment). As the fellow eye has an increased risk of developing giant retinal tear and retinal detachment, prophylactic 360-degree treatments with laser photocoagulation, cryotherapy or encircling scleral buckling have been proposed to reduce this risk. This review did not find any strong evidence in the form of prospective randomised controlled trials or case-control studies to support or refute these prophylactic treatments.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-12-12 18:21:06 +0000" MODIFIED_BY="Anupa Shah">
<ABS_BACKGROUND MODIFIED="2009-10-30 09:49:27 +0000" MODIFIED_BY="[Empty name]">
<P>A giant retinal tear is a full-thickness retinal break that extends circumferentially around the retina for 90 degrees or more in the presence of a posteriorly detached vitreous. It causes significant visual morbidity from retinal detachment and proliferative vitreoretinopathy. The fellow eye of patients who have had a spontaneous giant retinal tear has an increased risk of developing a giant retinal tear, a retinal detachment or both. Interventions such as 360-degree encircling scleral buckling, 360-degree cryotherapy and 360-degree laser photocoagulation have been advocated by some ophthalmologists as prophylaxis for the fellow eye against the development of a giant retinal tear and/or a retinal detachment, or to prevent its extension.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-02 16:03:23 +0000" MODIFIED_BY="Anupa Shah">
<P>To evaluate the effectiveness of prophylactic 360-degree interventions in the fellow eye of patients with unilateral giant retinal tear to prevent the occurrence of a giant retinal tear, a retinal detachment or both.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-12-12 14:46:43 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (<I>The Cochrane Library</I> 2011, Issue 11), MEDLINE (January 1950 to December 2011), EMBASE (January 1980 to December 2011), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to December 2011), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 6 December 2011. In addition, we searched the proceedings of the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) up to 2008 for information about other relevant studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-12-12 18:21:06 +0000" MODIFIED_BY="Anupa Shah">
<P>Prospective randomised controlled trials (RCTs) comparing one prophylactic treatment for fellow eyes of patients with giant retinal tear against observation (no treatment) or another form of prophylactic treatment. In the absence of RCTs, we planned to discuss case-control studies that met the inclusion criteria but we would not conduct a meta-analysis using these studies.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-02-09 12:54:34 +0000" MODIFIED_BY="Anupa Shah">
<P>We did not find any studies that met the inclusion criteria for the review and therefore no assessment of methodological quality or meta-analysis could be performed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-01 14:29:56 +0000" MODIFIED_BY="[Empty name]">
<P>No studies met the inclusion criteria for this review.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-01-22 23:40:47 +0000" MODIFIED_BY="[Empty name]">
<P>No strong evidence in the literature was found to support or refute prophylactic 360-degree treatments to prevent a giant retinal tear or a retinal detachment in the fellow eye of patients with unilateral giant retinal tears.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-12-12 18:21:25 +0000" MODIFIED_BY="Anupa Shah">
<BACKGROUND MODIFIED="2009-11-02 16:00:56 +0000" MODIFIED_BY="Anupa Shah">
<CONDITION MODIFIED="2009-11-02 16:00:24 +0000" MODIFIED_BY="Anupa Shah">
<P>A giant retinal tear (GRT) is a full-thickness retinal break that extends circumferentially around the retina for three or more clock hours (90 degrees or more) in the presence of a posteriorly detached vitreous (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Glasspool-1973" TYPE="REFERENCE">Glasspool 1973</LINK>; <LINK REF="REF-Kanski-1975" TYPE="REFERENCE">Kanski 1975</LINK>; <LINK REF="REF-Schepens-1962" TYPE="REFERENCE">Schepens 1962</LINK>; <LINK REF="REF-Scott-1975" TYPE="REFERENCE">Scott 1975</LINK>). It is an uncommon retinal condition with a guarded prognosis, as it can cause significant visual morbidity from retinal detachment. Recurrent retinal detachment, predominantly due to proliferative vitreoretinopathy (PVR), occurs in up to 49% of GRT cases (<LINK REF="REF-Ghosh-2004" TYPE="REFERENCE">Ghosh 2004</LINK>; <LINK REF="REF-Kertes-1997" TYPE="REFERENCE">Kertes 1997</LINK>; <LINK REF="REF-Malbran-1990" TYPE="REFERENCE">Malbran 1990</LINK>; <LINK REF="REF-Rofail-2005" TYPE="REFERENCE">Rofail 2005</LINK>; <LINK REF="REF-Scott-2002" TYPE="REFERENCE">Scott 2002</LINK>). Proliferative vitreoretinopathy is a scarring process that can occur on the inner or outer retinal surface and in the vitreous cavity following retinal detachment, which may lead to surgical failure even following initial successful surgical repair. The high incidence of PVR from GRT (up to 78%) may be due to several factors, including the release of a high number of retinal pigment epithelial cells from the subretinal space into the vitreous cavity as a result of the large area of exposed retinal pigment epithelium, and the increased cytokine production by these cells and by blood-borne cells from any concurrent clinical or sub-clinical associated vitreous haemorrhage (<LINK REF="REF-Duquesne-1996" TYPE="REFERENCE">Duquesne 1996</LINK>; <LINK REF="REF-Girard-1994" TYPE="REFERENCE">Girard 1994</LINK>; <LINK REF="REF-Kon-1999" TYPE="REFERENCE">Kon 1999</LINK>; <LINK REF="REF-Leaver-1981" TYPE="REFERENCE">Leaver 1981</LINK>; <LINK REF="REF-Malbran-1990" TYPE="REFERENCE">Malbran 1990</LINK>; <LINK REF="REF-Tseng-2004" TYPE="REFERENCE">Tseng 2004</LINK>; <LINK REF="REF-Yeung-2008" TYPE="REFERENCE">Yeung 2008</LINK>; <LINK REF="REF-Yoshino-1989" TYPE="REFERENCE">Yoshino 1989</LINK>). Surgical treatment of GRT can therefore be extremely challenging.</P>
<P>The annual incidence of GRT has not been clearly established in the literature. It has been estimated to be 0.05 per 100,000 of the general population per year, or 0.5% of all cases of retinal detachments resulting from retinal breaks (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>). Predisposing factors for the development of a GRT include trauma, complicated and uncomplicated intraocular procedures, refractive surgery, acute retinal necrosis, high myopia and hereditary vitreoretinopathies such as Stickler syndrome (<LINK REF="REF-Aaberg-1997" TYPE="REFERENCE">Aaberg 1997</LINK>; <LINK REF="REF-Abu-el_x002d_Asrar-1997" TYPE="REFERENCE">Abu el-Asrar 1997</LINK>; <LINK REF="REF-Aylward-1993" TYPE="REFERENCE">Aylward 1993</LINK>; <LINK REF="REF-Batman-1998" TYPE="REFERENCE">Batman 1998</LINK>; <LINK REF="REF-Clarkson-1984" TYPE="REFERENCE">Clarkson 1984</LINK>; <LINK REF="REF-Duguid-2000" TYPE="REFERENCE">Duguid 2000</LINK>; <LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>; <LINK REF="REF-Hernaez_x002d_Ortega-2004" TYPE="REFERENCE">Hernaez-Ortega 2004</LINK>; <LINK REF="REF-Kanski-1975" TYPE="REFERENCE">Kanski 1975</LINK>; <LINK REF="REF-Lash-2004" TYPE="REFERENCE">Lash 2004</LINK>; <LINK REF="REF-Moore-2003" TYPE="REFERENCE">Moore 2003</LINK>; <LINK REF="REF-Navarro-2005" TYPE="REFERENCE">Navarro 2005</LINK>; <LINK REF="REF-Ozdamar-1998" TYPE="REFERENCE">Ozdamar 1998</LINK>; <LINK REF="REF-Rizzo-2003" TYPE="REFERENCE">Rizzo 2003</LINK>; <LINK REF="REF-Schepens-1962" TYPE="REFERENCE">Schepens 1962</LINK>; <LINK REF="REF-Schipper-2000" TYPE="REFERENCE">Schipper 2000</LINK>; <LINK REF="REF-Scott-1975" TYPE="REFERENCE">Scott 1975</LINK>; <LINK REF="REF-Topilow-1982" TYPE="REFERENCE">Topilow 1982</LINK>; <LINK REF="REF-Vilaplana-1999" TYPE="REFERENCE">Vilaplana 1999</LINK>; <LINK REF="REF-Yam-2008" TYPE="REFERENCE">Yam 2008</LINK>). Other more rare conditions that have been associated with GRT include aniridia, lens coloboma, microspherophakia, retinitis pigmentosa, endogenous endophthalmitis and Jarisch-Herxheimer reaction in ocular syphilis (<LINK REF="REF-Cahill-1998" TYPE="REFERENCE">Cahill 1998</LINK>; <LINK REF="REF-Dowler-1995" TYPE="REFERENCE">Dowler 1995</LINK>; <LINK REF="REF-Hovland-1968" TYPE="REFERENCE">Hovland 1968</LINK>; <LINK REF="REF-Jain-2002" TYPE="REFERENCE">Jain 2002</LINK>; <LINK REF="REF-Johnston-1985" TYPE="REFERENCE">Johnston 1985</LINK>; <LINK REF="REF-Kim-1996" TYPE="REFERENCE">Kim 1996</LINK>; <LINK REF="REF-Pal-2005" TYPE="REFERENCE">Pal 2005</LINK>; <LINK REF="REF-Pournaras-2006" TYPE="REFERENCE">Pournaras 2006</LINK>). Patients usually present with acute, painless loss of vision in the affected eye. There may be preceding symptoms of flashing lights, floaters and/or a shadow over the field of vision. Dilated fundoscopy will confirm the diagnosis of GRT and the likely associated retinal detachment. Ultrasonography typically shows discontinuity of the high reflective linear retinal echo extending for more than three clock hours (<LINK REF="REF-Jalkh-1983" TYPE="REFERENCE">Jalkh 1983</LINK>). In addition, there is posterior vitreous detachment and, commonly, a central vitreous cavity due to vitreous syneresis and liquefaction (<LINK REF="REF-Genovesi_x002d_Ebert-1998" TYPE="REFERENCE">Genovesi-Ebert 1998</LINK>). Ultrasound is particularly useful in the event where no clear fundal view is achieved. It is also helpful to differentiate a GRT from a giant retinal dialysis, in which no posterior vitreous detachment would be observed.</P>
<P>The fellow eye of patients with a GRT, especially in spontaneous non-traumatic cases, has an increased risk for developing GRT and retinal detachment. The development of bilateral GRT has been found to occur in 12.8% (average interval 3.5 years and maximum interval six years); this has been reported to be as high as 74% within five years for GRT occurring at the equator (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>; <LINK REF="REF-Scott-1976" TYPE="REFERENCE">Scott 1976</LINK>). In Freeman's natural history series of 124 untreated fellow eyes, GRT occurred in 14 (11.3%) over a mean follow up of 3.7 years (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>). Furthermore, retinal detachments of any aetiology may occur in up to 36% of fellow eyes (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>; <LINK REF="REF-Glasspool-1973" TYPE="REFERENCE">Glasspool 1973</LINK>). Therefore, prophylactic treatments that may prevent the occurrence of GRT and retinal detachment or limit their extension would be extremely helpful to preserve vision in these patients.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-11-02 16:00:56 +0000" MODIFIED_BY="Anupa Shah">
<P>Various prophylactic 360-degree interventions have been advocated to reduce the risk of GRT and retinal detachment in the fellow eye, including circumferential encircling scleral buckling, cryotherapy and laser photocoagulation (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>; <LINK REF="REF-Ghosh-2004" TYPE="REFERENCE">Ghosh 2004</LINK>; <LINK REF="REF-Glasspool-1973" TYPE="REFERENCE">Glasspool 1973</LINK>; <LINK REF="REF-Govan-1981" TYPE="REFERENCE">Govan 1981</LINK>; <LINK REF="REF-Wolfensberger-2003" TYPE="REFERENCE">Wolfensberger 2003</LINK>). For encircling scleral buckles, a 360-degree silicone band is placed around the globe behind the insertion of the four rectus muscles and sutured to the sclera. The position of the encirclement varies in the literature: at the equator, or over areas of identified retinal pathology (<LINK REF="REF-Glasspool-1973" TYPE="REFERENCE">Glasspool 1973</LINK>; <LINK REF="REF-Hudson-1973" TYPE="REFERENCE">Hudson 1973</LINK>). This is a surgical procedure that requires general anaesthesia or local anaesthesia via the retrobulbar, peribulbar or sub-tenon routes with the subsequent risks and cost implications.</P>
<P>Cryotherapy is a technique that utilises intense cold from rapidly expanding very cold gases (usually nitrous oxide) to destroy choroidal and retinal tissue in order to form a chorioretinal scar. The cryotherapy is applied transsclerally or transconjunctivally, usually in one contiguous row, via a freezing probe at the peripheral retina throughout 360 degrees. The resultant 360-degree chorioretinal scar increases the adhesion between the neurosensory retina and the retinal pigment epithelium. Different areas for cryotherapy have been advocated, with treatment at the post-oral retina, at the posterior border of the vitreous base as determined by areas of &#8220;white-with-pressure&#8221;, and at the equator all having been described (<LINK REF="REF-Ang-2008" TYPE="REFERENCE">Ang 2008</LINK>; <LINK REF="REF-Govan-1981" TYPE="REFERENCE">Govan 1981</LINK>; <LINK REF="REF-Hudson-1977" TYPE="REFERENCE">Hudson 1977</LINK>; <LINK REF="REF-Robertson-1979" TYPE="REFERENCE">Robertson 1979</LINK>; <LINK REF="REF-Wolfensberger-2003" TYPE="REFERENCE">Wolfensberger 2003</LINK>). Like scleral buckling, cryotherapy requires general anaesthesia or local anaesthesia via the retrobulbar, peribulbar or sub-tenon routes and is not often performed as an outpatient procedure.</P>
<P>In laser photocoagulation, the light energy from the laser is converted to thermal energy by the pigment contained in the retinal pigment epithelium. This thermal energy subsequently destroys the retinal pigment epithelium and leads to the formation of a chorioretinal scar, with a resultant increased adhesion between the neurosensory retina and retinal pigment epithelium. It involves applying multiple, small-sized (up to 500 microns), high-intensity laser burns to the peripheral retina over three to six rows throughout 360 degrees via direct or indirect viewing systems. Most published series in which this prophylactic method was used describe the application of laser to the equatorial retina; in some the laser was extended to the ora serrata with four anterior radial rows, while in others laser treatment was applied circumferentially posterior to the areas of vitreoretinal degeneration (<LINK REF="REF-Brasseur-1985" TYPE="REFERENCE">Brasseur 1985</LINK>; <LINK REF="REF-Haut-1987" TYPE="REFERENCE">Haut 1987</LINK>; <LINK REF="REF-Haut-1991" TYPE="REFERENCE">Haut 1991</LINK>; <LINK REF="REF-Madelain-1990" TYPE="REFERENCE">Madelain 1990</LINK>; <LINK REF="REF-Meyer_x002d_Schwickerath-1967" TYPE="REFERENCE">Meyer-Schwickerath 1967</LINK>; <LINK REF="REF-Pollack-1994" TYPE="REFERENCE">Pollack 1994</LINK>). Unlike scleral buckling and cryotherapy, it is possible to perform laser as an outpatient procedure and without the need for general or even local anaesthesia, with the subsequent reduced risk and cost of the intervention.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-10-30 10:51:58 +0000" MODIFIED_BY="[Empty name]">
<P>It is believed that GRT would occur in areas of abnormal vitreoretinal adhesion and traction, often at the vitreous base, especially when there are already pre-existing vitreoretinal degenerations that could predispose to the development of retinal breaks (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Schepens-1962" TYPE="REFERENCE">Schepens 1962</LINK>; <LINK REF="REF-Scott-1976" TYPE="REFERENCE">Scott 1976</LINK>). A 360-degree encircling buckle would reduce the internal circumference of the eye at the site it is placed, thus reducing the amount of peripheral vitreoretinal traction. Cryotherapy and laser photocoagulation would result in an increased neurosensory retina-retinal pigment epithelium adhesion (scar) over 360 degrees and would likely reduce the risk of neurosensory retinal detachment from the retinal pigment epithelium and/or limit its extension if it were to occur.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-10-30 11:03:38 +0000" MODIFIED_BY="[Empty name]">
<P>There is a strong argument in favour of using 360-degree prophylaxis in fellow eyes of patients that have had a GRT, particularly in spontaneous non-traumatic cases and those associated with inherited vitreoretinal disorders, such as Stickler syndrome. However, prophylactic interventions are not without possible adverse effects, such as uveitis, cystoid macular oedema, epiretinal membrane formation and iatrogenic retinal breaks, among others (<LINK REF="REF-Bonnet-1987" TYPE="REFERENCE">Bonnet 1987</LINK>; <LINK REF="REF-Govan-1981" TYPE="REFERENCE">Govan 1981</LINK>; <LINK REF="REF-Haut-1987" TYPE="REFERENCE">Haut 1987</LINK>; <LINK REF="REF-Hudson-1977" TYPE="REFERENCE">Hudson 1977</LINK>; <LINK REF="REF-Madelain-1990" TYPE="REFERENCE">Madelain 1990</LINK>; <LINK REF="REF-Pollack-1994" TYPE="REFERENCE">Pollack 1994</LINK>; <LINK REF="REF-Robertson-1979" TYPE="REFERENCE">Robertson 1979</LINK>). Although uncommon, they may result in reduction in vision. To the patient, prophylactic treatments may represent a hassle and a cause of discomfort. Furthermore, it is not certain whether or not these prophylactic measures would reduce the risk of GRT, retinal detachment and/or visual loss. Retinal detachment may still ensue if subsequent retinal breaks develop posterior to the treated areas. Even if these prophylactic treatments were to be helpful, there is no clear knowledge on which of them is most effective. It is therefore important to review the current evidence in favour of or against prophylaxis in fellow eyes of patients with unilateral GRT.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-09 12:55:35 +0000" MODIFIED_BY="Anupa Shah">
<P>The primary objective of this review is to determine whether or not prophylactic 360-degree treatment against GRT is effective in reducing the risk of GRT, retinal detachment and subsequent visual loss in the fellow eye of patients with a unilateral GRT.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-12-12 18:21:25 +0000" MODIFIED_BY="Anupa Shah">
<SELECTION_CRITERIA MODIFIED="2011-12-12 18:21:25 +0000" MODIFIED_BY="Anupa Shah">
<CRIT_STUDIES MODIFIED="2011-12-12 18:21:25 +0000" MODIFIED_BY="Anupa Shah">
<P>We planned to include randomised controlled trials (RCTs) but if none met our inclusion criteria, we would discuss case-control studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-01-18 21:46:21 +0000" MODIFIED_BY="[Empty name]">
<P>Any participant with a unilateral GRT, independent of their age, gender or ethnicity and independently of the aetiology of the GRT, was eligible for inclusion in this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-02-09 12:55:43 +0000" MODIFIED_BY="Anupa Shah">
<P>The prophylactic interventions were 360-degree encircling scleral buckling, 360-degree transscleral cryotherapy and 360-degree laser photocoagulation. Studies comparing one of these prophylactic treatments against no treatment (control) or against another form of prophylactic treatment were included in this review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-02-09 12:56:25 +0000" MODIFIED_BY="Anupa Shah">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-02-09 12:55:47 +0000" MODIFIED_BY="Anupa Shah">
<OL>
<LI>Relative risk of patients with unilateral GRT developing a GRT in the fellow eye within three years following prophylactic treatment compared to those that did not receive prophylactic treatment.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-02-09 12:56:25 +0000" MODIFIED_BY="Anupa Shah">
<OL>
<LI>Relative risk of patients with unilateral GRT developing a retinal detachment in the fellow eye within three years following prophylactic treatment compared to those that did not receive prophylactic treatment.</LI>
<LI>Relative risk of patients with unilateral GRT developing a fovea-off retinal detachment in the fellow eye within three years following prophylactic treatment compared to those that did not receive prophylactic treatment.</LI>
<LI>Difference in the mean extension of GRT circumferentially (in clock hours) in the fellow eye within three years in those receiving prophylactic treatment compared to those that did not receive prophylactic treatment, and its standard error.</LI>
<LI>Difference in the mean extension of retinal detachment (in quadrants) in the fellow eye within three years in those receiving prophylactic treatment compared to those that did not receive prophylactic treatment, and its standard error.</LI>
<LI>Relative risk in patients with unilateral GRT of a decrease in Snellen visual acuity of two lines or more from baseline in the fellow eye within three years following prophylactic treatment compared to those that did not receive prophylactic treatment.</LI>
<LI>Relative risk of patients with unilateral GRT developing complications in the fellow eye from the prophylactic treatments within three years, compared to those that did not receive prophylactic treatment.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="5">Adverse outcomes</HEADING>
<P>The main adverse outcomes of prophylactic treatments will be classified into two categories:</P>
<OL>
<LI>Adverse outcomes with the potential to affect vision: these include refractive errors, raised intraocular pressure, anterior segment ischaemia, cataract, anterior and/or posterior uveitis, cystoid macular oedema, epiretinal membrane, retinal breaks and diplopia. Although some of these are likely to be the result of the prophylactic interventions (refractive errors, anterior segment ischaemia, uveitis, cystoid macular oedema, epiretinal membrane and diplopia), others may be coincidental (cataract) or related to the underlying disorder (retinal breaks). We also summarised any other adverse effects reported in the included studies with the potential to affect vision.</LI>
<LI>Adverse outcomes causing other symptoms but not affecting vision: these included discomfort, dryness and exposure of the encirclement elements, among others.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Economic data</HEADING>
<P>Economic data were not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life data</HEADING>
<P>Quality of life data were not available.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-12-12 16:08:20 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-12-12 16:08:20 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, Issue 11, part of <I>The Cochrane Library</I>. <A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A> (accessed 6 December 2011), MEDLINE (January 1950 to December 2011), EMBASE (January 1980 to December 2011), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to December 2011), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 6 December 2011.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), <I>m</I>RCT (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), ClinicalTrials.gov (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) and the ICTRP (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-02-09 12:56:56 +0000" MODIFIED_BY="Anupa Shah">
<P>We searched the reference lists of the retrieved articles and the proceedings of the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) for information about other relevant studies on prophylaxis of GRT in the fellow eye of patients with unilateral GRT. We searched the ARVO meeting abstracts from 1962 to 2008.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-12-12 18:18:35 +0000" MODIFIED_BY="Anupa Shah">
<STUDY_SELECTION MODIFIED="2009-11-02 16:01:01 +0000" MODIFIED_BY="Anupa Shah">
<P>Two authors independently assessed the titles and abstracts of all reports identified by the electronic and manual searches. Each report was labelled 'definitely exclude', 'unsure' or 'definitely include'. We excluded studies labelled as 'definitely exclude' from the review. We reassessed studies labelled as 'unsure' according to the inclusion criteria for this review. We assessed studies labelled as 'definitely include' for methodological quality. We resolved any differences between the two authors with regards to the above classification by discussion. We found all studies to be classified as 'definitely exclude' and, thus, identified no studies that met the inclusion criteria.</P>
<P>In future updates of this review, if we find RCTs that meet our inclusion criteria, we will follow the methodological process identified below.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-12-12 16:10:25 +0000" MODIFIED_BY="Anupa Shah">
<P>Two authors will extract data independently using a paper form developed by the Cochrane Eyes and Vision Group. Two authors will check the data independently before it is entered in to RevMan (<LINK REF="REF-Review-Manager-2011" TYPE="REFERENCE">Review Manager 2011</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-12-12 18:17:57 +0000" MODIFIED_BY="Anupa Shah">
<P>We will assess the risk of bias of any included studies according to the guidelines in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We will consider the following criteria: </P>
<UL>
<LI>Random sequence generation: we will describe the method used to generate the allocation sequence in detail.</LI>
<LI>Allocation concealment: we will describe the method used to conceal the allocation sequence.</LI>
<LI>Masking (blinding) of participants and outcome assessors will be noted.</LI>
<LI>Incomplete outcome data: we will describe exclusions, rates of follow up, reason for loss to follow up and intention-to-treat analysis.</LI>
<LI>Selective outcome reporting will be evaluated.</LI>
<LI>Other potential sources of bias will be discussed.</LI>
</UL>
<P>We will grade each of the above domains graded as:</P>
<UL>
<LI>high risk of bias: when plausible bias seriously weakens the study results;</LI>
<LI>low risk of bias: when plausible bias is unlikely to alter the study results; or</LI>
<LI>unclear risk of bias: when plausible bias raises some doubt about the study results.</LI>
</UL>
<P>If any of the above domains is graded as 'unclear risk of bias', we will contact the investigators of the published eligible RCTs in order to obtain additional information. In the event of failure to communicate with the study investigators or failure to respond within a reasonable time period, we will assess the methodological quality of that trial based on the available information. We will resolve any disagreements on the above assessments between the authors through discussion until a consensus is reached.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-12-12 18:18:35 +0000" MODIFIED_BY="Anupa Shah">
<P>We will summarise dichotomous outcomes as relative risk ratios, which will include:</P>
<OL>
<LI>relative risk of developing GRT in the fellow eye;</LI>
<LI>relative risk of developing a retinal detachment in the fellow eye;</LI>
<LI>relative risk of developing a fovea-off retinal detachment in the fellow eye;</LI>
<LI>relative risk of a decrease in Snellen visual acuity of two lines or more from baseline in the fellow eye; and</LI>
<LI>relative risk of developing complications from the prophylactic treatments in the fellow eye.</LI>
</OL>
<P>We will summarise continuous outcomes as difference in means and its standard error, which will include:</P>
<OL>
<LI>difference in mean extent of GRT circumferentially (in clock hours) in the fellow eye, and its standard error; and</LI>
<LI>difference in mean extent of retinal detachment (in quadrants) in the fellow eye, and its standard error.</LI>
</OL>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-12-05 23:24:19 +0000" MODIFIED_BY="[Empty name]">
<P>In the analysis, we will compare treated fellow eyes with non-treated fellow eyes in patients with unilateral GRT.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-12-12 18:15:56 +0000" MODIFIED_BY="Anupa Shah">
<P>We expect studies to be analyzed on an intention-to-treat basis. If there is no information about the characteristics of any missing data, this will raise concerns regarding whether the missing data may introduce any bias or not. Where data are missing or unclear, we will contact the authors for clarification and further information.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-12-12 14:53:10 +0000" MODIFIED_BY="Anupa Shah">
<P>We will test for heterogeneity by looking at the overlap in confidence intervals of the forest plot, and using the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic as defined in Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). We will use the I<SUP>2</SUP> statistic to assess the proportion of total variability explained by heterogeneity between studies.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-01-18 21:53:34 +0000" MODIFIED_BY="[Empty name]">
<P>We will assess sequence generation, allocation concealment, masking of participants and outcome assessors, incomplete outcome data, selective outcome reporting and other potential sources of bias as above. We will use funnel plots to assess publication bias in reported studies.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-12-12 14:18:22 +0000" MODIFIED_BY="Anupa Shah">
<P>We will perform data analysis according to the guidelines set out in Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). We will use a random-effects model. If there is no statistical or clinical heterogeneity, or if the number of trials is fewer than three, we will use a fixed-effect model to avoid reporting potential poor effect estimates due to random-effects models in situations with very few trials.</P>
<P>We will perform a meta-analysis for the following outcomes: relative risk of developing a GRT in the fellow eye within three years (primary outcome), relative risk of developing a retinal detachment in the fellow eye within three years (secondary outcome), and relative risk of a decrease in Snellen visual acuity of two lines or more from baseline in the fellow eye within three years (secondary outcome).</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-02-09 12:58:32 +0000" MODIFIED_BY="Anupa Shah">
<P>We will examine the impact of excluding studies with lower methodological quality, unpublished data and industry funded data in sensitivity analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-12-12 17:55:42 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-12-12 17:55:42 +0000" MODIFIED_BY="[Empty name]">
<P>The electronic searches found 162 titles and abstracts. The Trials Search Co-ordinator scanned the search results and removed 144 references which were not relevant to the scope of the review. We scanned the remaining 18 references but none met the inclusion criteria. We then searched the reference lists of the retrieved articles to identify additional studies and found 54 citations. Of these, we excluded 43 references: 22 evaluated prophylactic treatment of predisposing vitreoretinal lesions while 21 assessed prophylactic treatment of fellow eyes of retinal detachments; these were not specifically investigating fellow eyes of GRT. Only 12 articles were pertinent to the review, but none were RCTs or case-control studies. There were only five publications describing 360-degree prophylaxis in GRT fellow eyes that had a sample size of three or more.</P>
<P>Of the 12 articles mentioned above, two were referring to local treatment of predisposing vitreoretinal lesions and nine to circumferential treatment over 360 degrees for fellow eyes of patients with unilateral GRT.</P>
<P>Local prophylactic treatments were evaluated in two case series; one investigated the role of local treatments to predisposing lesions or high-risk areas in 11 GRT fellow eyes (<LINK REF="REF-Kreissig-1983" TYPE="REFERENCE">Kreissig 1983</LINK>). The other evaluated local treatments for 150 retinal detachment fellow eyes considered at &#8220;high risk&#8221;; these included five GRT fellow eyes (<LINK REF="REF-Mastropasqua-1999" TYPE="REFERENCE">Mastropasqua 1999</LINK>).</P>
<P>The ten publications describing 360-degree treatments consisted of two case reports and eight retrospective case series. The two case reports comprised three fellow eyes of patients with GRT, and described prophylaxis with 360-degree laser photocoagulation (<LINK REF="REF-Brasseur-1985" TYPE="REFERENCE">Brasseur 1985</LINK>; <LINK REF="REF-Meyer_x002d_Schwickerath-1967" TYPE="REFERENCE">Meyer-Schwickerath 1967</LINK>).</P>
<P>Of the eight retrospective case series, one assessed prophylactic 360-degree cryotherapy in 48 fellow eyes of spontaneous GRT (<LINK REF="REF-Wolfensberger-2003" TYPE="REFERENCE">Wolfensberger 2003</LINK>). The second case series described 55 eyes that had prophylactic treatment with either 360-degree encircling scleral buckle at the equator for &#8220;higher risk&#8221; eyes or local cryotherapy to &#8220;lower risk&#8221; eyes with predisposing vitreoretinal lesions (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>). The third series predominantly focused on the prognostic factors of GRT outcomes following vitrectomy in 117 eyes, but included 21 fellow eyes of spontaneous GRT treated with either 360-degree cryotherapy or laser photocoagulation (<LINK REF="REF-Al_x002d_Khairi-2008" TYPE="REFERENCE">Al-Khairi 2008</LINK>). The fourth study evaluated 360-degree cryotherapy in fellow eyes of GRT, aphakic retinal detachment and high myopia, and included 18 GRT fellow eyes (<LINK REF="REF-Govan-1981" TYPE="REFERENCE">Govan 1981</LINK>). The fifth case series primarily investigated the surgical treatment and outcome of GRT in 29 eyes, but also described the outcomes of prophylactic 360-degree laser photocoagulation or cryotherapy in 18 fellow eyes (<LINK REF="REF-Ghosh-2004" TYPE="REFERENCE">Ghosh 2004</LINK>). The sixth assessed 360-degree encircling scleral buckle in conjunction with local cryotherapy for the fellow eye of three patients (<LINK REF="REF-Glasspool-1973" TYPE="REFERENCE">Glasspool 1973</LINK>). Details on these six case series are provided in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and will be discussed below.</P>
<P>The seventh case series evaluated 360-degree encircling buckle for fellow eyes of retinal detachment, and included two GRT fellow eyes (<LINK REF="REF-Hudson-1973" TYPE="REFERENCE">Hudson 1973</LINK>). The final series reported 360-degree cryotherapy for patients with Type 1 Stickler syndrome, which is the commonest inherited cause of GRT (<LINK REF="REF-Ang-2008" TYPE="REFERENCE">Ang 2008</LINK>). This series included 31 eyes of 31 patients with this disease who have had a retinal detachment in the first eye; however, data on the number of first eyes with GRT in the first eye were unavailable.</P>
<P>An update search was done in October 2009. After deduplication the search identified a total of 14 references. Two authors independently reviewed the references but did not find any relevant reports of trials.</P>
<P>A further update search was done in December 2011. After deduplication the search identified a total of 25 references. The Trials Search Co-ordinator scanned the search results and removed 24 references which were not relevant to the scope of the review. We reviewed the remaining reference but it did not meet the inclusion criteria for the review.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-27 15:28:49 +0000" MODIFIED_BY="Anupa Shah">
<P>As no studies fulfilled the inclusion criteria for the review, risk of bias was not assessed.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-27 15:28:55 +0000" MODIFIED_BY="Anupa Shah">
<P>As no studies fulfilled the inclusion criteria for the review, the effect of interventions could not be assessed.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-05 11:55:22 +0000" MODIFIED_BY="Anupa Shah">
<P>This review found no prospective RCTs or case-control studies on prophylactic treatments for fellow eyes of patients with unilateral GRT. The literature on this topic is scarce.</P>
<P>In the largest case series (48 eyes) of prophylactic 360-degree cryotherapy administered to fellow eyes of patients with spontaneous GRT, only one (2.1%) fellow eye developed GRT and two others (4.2%) developed a non-GRT retinal detachment after a mean follow up of 84 months (<LINK REF="REF-Wolfensberger-2003" TYPE="REFERENCE">Wolfensberger 2003</LINK>). The fellow eye that developed GRT did so six months after prophylactic cryotherapy; the two non-GRT retinal detachments occurred after 11 and 36 months respectively. No complications were described, but the possibility of the GRT and two retinal detachments occurring as a result of the 360-degree cryotherapy could not be excluded.</P>
<P>Freeman's follow up of 226 non-traumatic GRT fellow eyes included 55 eyes that had prophylactic treatment with either 360-degree encircling scleral buckle for &#8220;higher risk&#8221; eyes or local cryotherapy to &#8220;lower risk&#8221; predisposing vitreoretinal lesions (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>). &#8220;Higher risk&#8221; eyes included those with retinal tears, high myopia and increasing white-with-pressure. Over a mean follow-up period of 44 months, one of the fellow eyes (treated with 360-degree scleral buckling) developed GRT, in contrast to 11.3% (14 of 124) in the untreated eyes. One (treated with local cryotherapy) developed a non-GRT retinal detachment, while this occurred in nine of the 124 (7.3%) untreated eyes. The only complication noted was transient vitreous haemorrhage in one eye that underwent 360-degree encircling scleral buckle.</P>
<P>Of the 117 GRT eyes in Al-Khairi's study, 21 were fellow eyes of spontaneous GRT that received either prophylactic 360-degree laser photocoagulation or cryotherapy, whilst a further 42 fellow eyes did not. After a mean duration of 30 months, only one of the 21 (4.8%) treated eyes experienced a retinal detachment. In contrast, among the 42 untreated fellow eyes, GRT occurred in two (4.8%) and retinal detachment in a further three (7.1%) (<LINK REF="REF-Al_x002d_Khairi-2008" TYPE="REFERENCE">Al-Khairi 2008</LINK>).</P>
<P>A separate study reported on 360-degree cryotherapy (one row) to the equator in 106 eyes considered at &#8216;high risk&#8217; of retinal detachment (18 GRT fellow eyes, 60 aphakic retinal detachment fellow eyes, 10 phakic retinal detachment fellow eyes, and 18 with high myopia) followed up over a mean of 29 months (<LINK REF="REF-Govan-1981" TYPE="REFERENCE">Govan 1981</LINK>). Of the 18 GRT fellow eyes, none developed GRT, however, three (16.7%) developed retinal detachment after 28, 36 and 54 months respectively. None were fovea-off detachments, with two (11.2%) occurring anterior to the cryotherapy barrier and one (5.6%) at an area of non-confluent scarring within the barrier. Complications were noted in 14 (13.2%) of the 106 treated eyes, but it was not stated if these occurred in the 18 treated GRT fellow eyes. The complications were acute anterior uveitis (three eyes), cystoid macular oedema following cataract surgery (three eyes), transient loss of accommodation (two eyes), fixed dilated pupil (one eye), cataract (one eye), vitreous haemorrhage (one eye), epiretinal membrane (one eye), retinal haemorrhage (one eye) and choroidal haemorrhage (one eye).</P>
<P>In a smaller case series of 29 patients with unilateral GRT, of which six were traumatic and 23 spontaneous, none of the 18 fellow eyes of spontaneous GRT treated prophylactically with 360-degree laser photocoagulation or cryotherapy developed GRT after a mean follow up of 28 months (<LINK REF="REF-Ghosh-2004" TYPE="REFERENCE">Ghosh 2004</LINK>). Of the remaining five untreated fellow eyes of spontaneous GRT, three developed GRT within two to four weeks of the primary GRT surgery, before prophylactic treatment could be performed. The other two eyes were not prophylactically treated in accordance with the patients' requests; neither developed GRT or retinal detachment after a follow up of 36 months.</P>
<P>The final case series described local cryotherapy to all retinal breaks and degenerative areas with additional 360-degree encircling scleral buckle so that the areas of retinal pathology would rest on the anterior slope of the indent. This was performed for three fellow eyes of patients with unilateral GRT; none developed a GRT or a retinal detachment after a mean follow up of 18 months (<LINK REF="REF-Glasspool-1973" TYPE="REFERENCE">Glasspool 1973</LINK>).</P>
<P>The results from the case series described above suggest that 360-degree prophylactic treatment of the fellow eye may reduce the risk of GRT (11.3% to 74% untreated; up to 2.1% treated), and possibly of non-GRT retinal detachment (7.3% to 36% untreated; up to 16.7% treated). Although no comparisons can be adequately established among these series, results do not indicate any significant advantage or disadvantage of one form of prophylaxis over the other. Any adverse effects from these interventions were mostly mild and self-limiting, and did not lead to visual loss. The complication rates in these studies compare favourably with the incidence of complications as reported for these interventions in the literature. Depending on the study, these range from 0% to 23.1% for 360-degree encircling scleral buckling, 0% to 13.2% for 360-degree cryotherapy, and 0% to 3.8% for 360-degree laser photocoagulation (<LINK REF="REF-Ang-2008" TYPE="REFERENCE">Ang 2008</LINK>; <LINK REF="REF-Govan-1981" TYPE="REFERENCE">Govan 1981</LINK>; <LINK REF="REF-Haut-1987" TYPE="REFERENCE">Haut 1987</LINK>; <LINK REF="REF-Haut-1991" TYPE="REFERENCE">Haut 1991</LINK>; <LINK REF="REF-Hudson-1973" TYPE="REFERENCE">Hudson 1973</LINK>; <LINK REF="REF-Hudson-1977" TYPE="REFERENCE">Hudson 1977</LINK>; <LINK REF="REF-Madelain-1990" TYPE="REFERENCE">Madelain 1990</LINK>; <LINK REF="REF-Pollack-1994" TYPE="REFERENCE">Pollack 1994</LINK>; <LINK REF="REF-Robertson-1979" TYPE="REFERENCE">Robertson 1979</LINK>).</P>
<P>As vitreous liquefaction and vitreous base contraction are important in GRT pathogenesis, 360-degree encircling scleral buckling may help by reducing the traction exerted by the vitreous base on the peripheral retina. This prophylactic method, however, entails a surgical procedure and is associated with buckle-related complications. Cryotherapy and laser photocoagulation would not reduce or prevent the occurrence of vitreous traction. Hence, retinal tears and subsequent retinal detachment could still occur and have been reported posterior to the cryotherapy and laser scars (<LINK REF="REF-Bonnet-1987" TYPE="REFERENCE">Bonnet 1987</LINK>). However, both increase the adhesion of the neurosensory retina to the retinal pigment epithelium, thus reducing the possibility of the development of retinal tears and limiting their extension and that of a subsequent retinal detachment.</P>
<P>Currently, there is no strong evidence in the form of a RCT or a case-control study to support or refute the use of 360-degree prophylactic treatments for fellow eyes of patients with unilateral GRT. Data from available case series, however, suggest a benefit of 360-degree prophylactic treatments in reducing the incidence of GRT and retinal detachments in fellow eyes of patients with unilateral GRT. Considering the observed increased risk in fellow eyes of patients with idiopathic GRT and of those with inherited vitreoretinal diseases such as Stickler syndrome, and the reported low rate of complications, 360-degree prophylactic treatments may be considered in these patients.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-02 16:02:02 +0000" MODIFIED_BY="Anupa Shah">
<IMPLICATIONS_PRACTICE MODIFIED="2009-02-17 16:33:33 +0000" MODIFIED_BY="Anupa Shah">
<P>There is currently no evidence in the form of prospective RCTs or case-control studies to support or refute the use of prophylactic 360-degree treatment of the fellow eye of patients with unilateral GRT. However, given the high incidence of GRT and retinal detachment reported in patients with idiopathic GRT and those associated with inherited vitreoretinal diseases such as Stickler syndrome, the observed reduced risk of GRT and retinal detachment following prophylaxis in published case series, and the relative low rate of complications of prophylactic treatments, prophylaxis of fellow eyes may be considered for these patients. Based on data from <LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK> and <LINK REF="REF-Wolfensberger-2003" TYPE="REFERENCE">Wolfensberger 2003</LINK>, although they may not be directly comparable, it can be estimated that the number of patients needed to treat (NNT) to prevent a GRT is 10.9, whilst the NNT to prevent a retinal detachment (related to a GRT or any other type of tear) is 8.1. This further suggests that prophylactic treatment is a reasonable option for fellow eyes of patients with unilateral GRT.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-02 16:02:02 +0000" MODIFIED_BY="Anupa Shah">
<P>Randomised controlled trials evaluating the clinical and cost-effectiveness of prophylaxis with 360-degree encircling scleral buckling treatments, cryotherapy or laser photocoagulation of fellow eyes of patients with unilateral GRT would be ideal to provide the strong evidence required to guide clinicians on the use of these prophylactic treatments. Such trials should compare one form of prophylactic treatment against observation (no treatment) or another form of treatment, be appropriately powered (i.e. sufficient numbers of participants) and have a relatively long-term follow up (over three years). However, undertaking such RCTs would be challenging. Considering the published incidence of GRT in fellow eyes (11.3% in untreated eyes (<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>) and 2.1% in treated eyes (95% confidence interval 0 to 6.1%; <LINK REF="REF-Wolfensberger-2003" TYPE="REFERENCE">Wolfensberger 2003</LINK>), a RCT with 655 patients per arm would be required to provide 90% power to detect a reduction in the incidence of GRT from 11.3% to 6.1% or less.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-12-12 18:08:22 +0000" MODIFIED_BY="Anupa Shah">
<P>We would like to thank Iris Gordon, Anupa Shah and the Cochrane Eyes and Vision Group (CEVG) for their assistance in preparing this review. CEVG created and executed the electronic search strategies. We would also like to thank Catey Bunce and Ann-Margret Ervin for their comments and Michel Paques and Emma Sydenham for assisting in translations of French and German articles.</P>
<P>Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-12-12 18:16:03 +0000" MODIFIED_BY="Anupa Shah">
<P>NL conceived the review question, provided a policy and consumer perspective, provided general advice and secured funding for the review.<BR/>GSA co-ordinated the review, undertook manual searches, organised retrieval of full-text copies.<BR/>NL and GSA screened the titles and abstracts of search results, screened retrieved papers against inclusion criteria, appraised quality of papers, wrote to authors of studies for additional information, provided additional data about papers, obtained and screened data for unpublished studies and provided a clinical perspective.<BR/>NL, GSA and JT extracted data from papers, entered data into RevMan, analyzed data, provided a methodological perspective and wrote the review.</P>
<P>Update of review Issue 2, 2011<BR/>GSA and Cochrane Eyes and Vision Group's (CEVG) Trials Search Co-ordinator (TSC) screened search results.<BR/>CEVG's Managing Editor and TSC updated the review (minor edits).<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-12-12 18:13:43 +0000" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-12-12 18:13:43 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-12-12 14:30:11 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aaberg-1997" MODIFIED="2009-01-27 16:16:08 +0000" MODIFIED_BY=" Iris Gordon" NAME="Aaberg 1997" TYPE="JOURNAL_ARTICLE">
<AU>Aaberg TM Jr, Rubsamen PE, Flynn HW Jr, Chang S, Mieler WF, Smiddy WE</AU>
<TI>Giant retinal tear as a complication of attempted removal of intravitreal lens fragments during cataract surgery</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1997</YR>
<VL>124</VL>
<NO>2</NO>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abu-el_x002d_Asrar-1997" MODIFIED="2009-01-27 16:18:51 +0000" MODIFIED_BY=" Iris Gordon" NAME="Abu el-Asrar 1997" TYPE="JOURNAL_ARTICLE">
<AU>Abu el-Asrar AM</AU>
<TI>Giant retinal tears after pars plana vitrectomy</TI>
<SO>Eye</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>Pt 3</NO>
<PG>325-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Al_x002d_Khairi-2008" MODIFIED="2009-06-25 15:50:56 +0100" MODIFIED_BY="[Empty name]" NAME="Al-Khairi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Al-Khairi AM, Al-Kahtani E, Kangave D, Abu el-Asrar AM</AU>
<TI>Prognostic factors associated with outcomes after giant retinal tear management using perfluorocarbon liquids</TI>
<SO>European Journal of Ophthalmology</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>2</NO>
<PG>270-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ang-2008" MODIFIED="2009-01-27 16:20:00 +0000" MODIFIED_BY=" Iris Gordon" NAME="Ang 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ang A, Poulson AV, Goodburn SF, Richards AJ, Scott JD, Snead MP</AU>
<TI>Retinal detachment and prophylaxis in Type 1 Stickler Syndrome</TI>
<SO>Ophthalmology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>1</NO>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aylward-1993" MODIFIED="2009-02-17 16:24:23 +0000" MODIFIED_BY="Anupa Shah" NAME="Aylward 1993" TYPE="JOURNAL_ARTICLE">
<AU>Aylward GW, Cooling RJ, Leaver PK</AU>
<TI>Trauma-induced retinal detachment associated with giant retinal tears</TI>
<SO>Retina</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>2</NO>
<PG>136-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Batman-1998" MODIFIED="2009-01-27 16:21:53 +0000" MODIFIED_BY=" Iris Gordon" NAME="Batman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Batman C, Cekic O</AU>
<TI>Giant retinal tears after pars plana vitrectomy</TI>
<SO>Eye</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>Pt 1</NO>
<PG>163-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonnet-1987" MODIFIED="2009-01-27 16:22:41 +0000" MODIFIED_BY=" Iris Gordon" NAME="Bonnet 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet M, Aracil P, Carneau F</AU>
<TI>Rhegmatogenous retinal detachment after prophylactic argon laser photocoagulation</TI>
<SO>Graefe's Archive of Clinical and Experimental Ophthalmology</SO>
<YR>1987</YR>
<VL>225</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brasseur-1985" MODIFIED="2011-12-12 14:10:12 +0000" MODIFIED_BY=" Iris Gordon" NAME="Brasseur 1985" TYPE="JOURNAL_ARTICLE">
<AU>Brasseur G, Charlin JF, Langlois J</AU>
<TI>The fellow eye in cases of giant tears of the retina. Preventive attitude</TI>
<TO>L'oeil adelphe dans les cas de dechirures geantes de la retine. Attitude prophylactique</TO>
<SO>Bulletin des Societes d'Ophtalmologie de France</SO>
<YR>1985</YR>
<VL>85</VL>
<NO>2</NO>
<PG>215-8</PG>
<IDENTIFIERS MODIFIED="2008-11-01 12:10:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Cahill-1998" MODIFIED="2009-01-27 16:25:40 +0000" MODIFIED_BY=" Iris Gordon" NAME="Cahill 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cahill MT, Barry PJ, Kenna PF</AU>
<TI>Giant retinal tear in Usher syndrome type II: coincidence or association?</TI>
<SO>Retina</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>177-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarkson-1984" MODIFIED="2009-01-27 16:26:33 +0000" MODIFIED_BY=" Iris Gordon" NAME="Clarkson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Clarkson JG, Blumenkranz MS, Culbertson WW, Flynn HW Jr, Lewis ML</AU>
<TI>Retinal detachment following the acute retinal necrosis syndrome</TI>
<SO>Ophthalmology</SO>
<YR>1984</YR>
<VL>91</VL>
<NO>12</NO>
<PG>1665-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2011-12-12 14:21:22 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dowler-1995" MODIFIED="2009-01-27 16:27:36 +0000" MODIFIED_BY=" Iris Gordon" NAME="Dowler 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dowler JG, Lyons CJ, Cooling RJ</AU>
<TI>Retinal detachment and giant retinal tears in aniridia</TI>
<SO>Eye</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>Pt 3</NO>
<PG>268-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duguid-2000" MODIFIED="2009-01-27 16:28:53 +0000" MODIFIED_BY=" Iris Gordon" NAME="Duguid 2000" TYPE="JOURNAL_ARTICLE">
<AU>Duguid IG, Leaver PK</AU>
<TI>Giant retinal tears resulting from eye gouging in rugby football</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>1</NO>
<PG>65-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duquesne-1996" MODIFIED="2009-01-27 16:29:42 +0000" MODIFIED_BY=" Iris Gordon" NAME="Duquesne 1996" TYPE="JOURNAL_ARTICLE">
<AU>Duquesne N, Bonnet M, Adeleine P</AU>
<TI>Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1996</YR>
<VL>234</VL>
<NO>11</NO>
<PG>677-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1978" NAME="Freeman 1978" TYPE="JOURNAL_ARTICLE">
<AU>Freeman HM</AU>
<TI>Fellow eyes of giant retinal breaks</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1978</YR>
<VL>76</VL>
<PG>343-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1979" MODIFIED="2009-01-18 22:02:47 +0000" MODIFIED_BY="[Empty name]" NAME="Freeman 1979" TYPE="JOURNAL_ARTICLE">
<AU>Freeman HM</AU>
<TI>Fellow eyes of giant retinal breaks</TI>
<SO>Modern Problems in Ophthalmology</SO>
<YR>1979</YR>
<VL>20</VL>
<PG>267-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Genovesi_x002d_Ebert-1998" MODIFIED="2009-01-27 16:33:38 +0000" MODIFIED_BY=" Iris Gordon" NAME="Genovesi-Ebert 1998" TYPE="JOURNAL_ARTICLE">
<AU>Genovesi-Ebert F, Rizzo S, Chiellini S, Di Bartolo E, Marabotti A, Nardi M</AU>
<TI>Echographic study of the vitreoretinal interface in giant retinal tears</TI>
<SO>Ophthalmologica</SO>
<YR>1988</YR>
<VL>212</VL>
<NO>Suppl 1</NO>
<PG>89-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghosh-2004" MODIFIED="2011-12-12 14:27:37 +0000" MODIFIED_BY=" Iris Gordon" NAME="Ghosh 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ghosh YK, Banerjee S, Savant V, Kotamarthi V, Benson MT, Scott RA, et al</AU>
<TI>Surgical treatment and outcome of patients with giant retinal tears</TI>
<SO>Eye</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>Pt 10</NO>
<PG>996-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Girard-1994" MODIFIED="2009-01-27 16:37:12 +0000" MODIFIED_BY=" Iris Gordon" NAME="Girard 1994" TYPE="JOURNAL_ARTICLE">
<AU>Girard P, Mimoun G, Karpouzas I, Montefiore G</AU>
<TI>Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery</TI>
<SO>Retina</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>5</NO>
<PG>417-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" MODIFIED="2009-01-27 16:38:10 +0000" MODIFIED_BY=" Iris Gordon" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glasspool-1973" MODIFIED="2009-01-22 12:15:13 +0000" MODIFIED_BY="[Empty name]" NAME="Glasspool 1973" TYPE="JOURNAL_ARTICLE">
<AU>Glasspool MG, Kanski JJ</AU>
<TI>Prophylaxis in giant tears</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1973</YR>
<VL>93</VL>
<PG>363-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Govan-1981" MODIFIED="2009-01-27 16:39:15 +0000" MODIFIED_BY=" Iris Gordon" NAME="Govan 1981" TYPE="JOURNAL_ARTICLE">
<AU>Govan JA</AU>
<TI>Prophylactic circumferential cryopexy: a retrospective study of 106 eyes</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1981</YR>
<VL>65</VL>
<NO>5</NO>
<PG>364-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haut-1987" MODIFIED="2009-01-27 16:40:27 +0000" MODIFIED_BY=" Iris Gordon" NAME="Haut 1987" TYPE="JOURNAL_ARTICLE">
<AU>Haut J, Monin C, Diner-Nedey S, Van Effenterre G</AU>
<TI>Prevention of bilateralization of idiopathic retinal detachment by treatment with argon laser</TI>
<SO>Journal Francais d'Ophtalmologie</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>11</NO>
<PG>717-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haut-1991" MODIFIED="2009-01-27 16:41:56 +0000" MODIFIED_BY=" Iris Gordon" NAME="Haut 1991" TYPE="JOURNAL_ARTICLE">
<AU>Haut J, Ladjimi A, Van Effenterre G, Monin C, Moulin F, Le Mer Y</AU>
<TI>Preventive treatment of retinal detachment of the contralateral eye. Results of 5 years follow-up of 109 eyes</TI>
<SO>Journal Francais d'Ophtalmologie</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>6-7</NO>
<PG>397-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hernaez_x002d_Ortega-2004" MODIFIED="2009-01-27 16:42:54 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hernaez-Ortega 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hernaez-Ortega MC, Soto-Pedre E</AU>
<TI>Giant retinal tear after iris claw phakic intraocular lens</TI>
<SO>Journal of Refractive Surgery</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>6</NO>
<PG>839-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-12-12 14:17:41 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hovland-1968" MODIFIED="2009-02-12 21:34:11 +0000" MODIFIED_BY="[Empty name]" NAME="Hovland 1968" TYPE="JOURNAL_ARTICLE">
<AU>Hovland KR, Schepens CL, Freeman HM</AU>
<TI>Developmental giant retinal tears associated with lens coloboma</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1968</YR>
<VL>80</VL>
<NO>3</NO>
<PG>325-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hudson-1973" MODIFIED="2009-01-27 16:43:56 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hudson 1973" TYPE="JOURNAL_ARTICLE">
<AU>Hudson JR, Kanski JJ, Elkington AR</AU>
<TI>Prophylactic encirclement</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1973</YR>
<VL>57</VL>
<NO>8</NO>
<PG>531-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hudson-1977" MODIFIED="2009-01-22 12:12:54 +0000" MODIFIED_BY="[Empty name]" NAME="Hudson 1977" TYPE="JOURNAL_ARTICLE">
<AU>HudsonJR, Kanski JJ</AU>
<TI>Prevention of aphakic retinal detachment by circumferential cryotherapy</TI>
<SO>Modern Problems in Ophthalmology</SO>
<YR>1977</YR>
<VL>18</VL>
<PG>530-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jain-2002" MODIFIED="2011-12-12 14:28:52 +0000" MODIFIED_BY=" Iris Gordon" NAME="Jain 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jain K, Lam W</AU>
<TI>Giant retinal tear and meningococcus endogenous endophthalmitis</TI>
<SO>Journal of AAPOS</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>4</NO>
<PG>259-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jalkh-1983" MODIFIED="2009-02-09 13:01:40 +0000" MODIFIED_BY="Anupa Shah" NAME="Jalkh 1983" TYPE="JOURNAL_ARTICLE">
<AU>Jalkh AE, Jabbour N, Avila MP, Trempe CL, Schepens CL</AU>
<TI>Ultrasonographic findings in eyes with giant retinal tears and opaque media</TI>
<SO>Retina</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>3</NO>
<PG>154-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnston-1985" MODIFIED="2009-01-27 16:47:24 +0000" MODIFIED_BY=" Iris Gordon" NAME="Johnston 1985" TYPE="JOURNAL_ARTICLE">
<AU>Johnston ME, Gonder JR</AU>
<TI>Giant retinal tears, retinal detachment and retinitis pigmentosa</TI>
<SO>Canadian Journal of Ophthalmology</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>1</NO>
<PG>16-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kanski-1975" MODIFIED="2009-01-27 16:48:56 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kanski 1975" TYPE="JOURNAL_ARTICLE">
<AU>Kanski JJ</AU>
<TI>Giant retinal tears</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1975</YR>
<VL>79</VL>
<NO>5</NO>
<PG>846-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kertes-1997" MODIFIED="2009-01-27 16:51:58 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kertes 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kertes PJ, Wafapoor H, Peyman GA, Calixto N Jr, Thompson H</AU>
<TI>The management of giant retinal tears using perfluoroperhydrophenanthrene. A multicenter case series. Vitreon Collaborative Study Group</TI>
<SO>Ophthalmology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>7</NO>
<PG>1159-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-1996" MODIFIED="2009-01-27 16:53:08 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kim 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kim RY, Schwartz SD, Heckenlively JR, Gregor ZJ, Cooling RJ</AU>
<TI>Giant retinal tear and retinal detachment with underlying retinitis pigmentosa and hearing loss</TI>
<SO>Eye</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>Pt 6</NO>
<PG>697-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kon-1999" MODIFIED="2009-01-27 16:58:04 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kon 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kon CH, Occleston NL, Aylward GW, Khaw PT</AU>
<TI>Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>1999</YR>
<VL>40</VL>
<NO>3</NO>
<PG>705-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kreissig-1983" MODIFIED="2011-12-12 14:29:37 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kreissig 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kreissig I, Robert Y</AU>
<TI>Prevention, in the contralateral eye, of a giant tear ablation</TI>
<TO>Beitrag zur prophylaxe am partnerauge einer riesenrissablatio</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1983</YR>
<VL>182</VL>
<NO>2</NO>
<PG>121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lash-2004" MODIFIED="2009-01-27 17:00:25 +0000" MODIFIED_BY=" Iris Gordon" NAME="Lash 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lash SC, Williams CP, Luff AJ, Hodgkins PR</AU>
<TI>360 degree giant retinal tear as a result of presumed non-accidental injury</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2004</YR>
<VL>88</VL>
<NO>1</NO>
<PG>155</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leaver-1981" MODIFIED="2009-01-22 12:06:34 +0000" MODIFIED_BY="[Empty name]" NAME="Leaver 1981" TYPE="JOURNAL_ARTICLE">
<AU>Leaver PK, Lean JS</AU>
<TI>Management of giant retinal tears using vitrectomy and silicone oil/fluid exchange. A preliminary report</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1981</YR>
<VL>101</VL>
<PG>189-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madelain-1990" MODIFIED="2009-01-27 17:01:34 +0000" MODIFIED_BY=" Iris Gordon" NAME="Madelain 1990" TYPE="JOURNAL_ARTICLE">
<AU>Madelain J, Turut P</AU>
<TI>Results of systematic preventive treatment with argon laser after idiopathic retinal detachment</TI>
<SO>Bulletin des Societes d'Ophtalmologie de France</SO>
<YR>1990</YR>
<VL>90</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malbran-1990" MODIFIED="2009-01-27 17:02:31 +0000" MODIFIED_BY=" Iris Gordon" NAME="Malbran 1990" TYPE="JOURNAL_ARTICLE">
<AU>Malbran E, Dodds RA, Hulsbus R, Charles DE, Buonsanti JL, Adrogue E</AU>
<TI>Retinal break type and proliferative vitreoretinopathy in nontraumatic retinal detachment</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1990</YR>
<VL>228</VL>
<NO>5</NO>
<PG>423-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mastropasqua-1999" MODIFIED="2009-01-27 17:05:21 +0000" MODIFIED_BY=" Iris Gordon" NAME="Mastropasqua 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mastropasqua L, Carpineto P, Ciancaglini M, Falconio G, Gallenga PE</AU>
<TI>Treatment of retinal tears and lattice degeneration in fellow eyes in high risk patients suffering retinal detachment: a prospective study</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>9</NO>
<PG>1046-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meyer_x002d_Schwickerath-1967" MODIFIED="2008-11-01 12:14:04 +0000" MODIFIED_BY="[Empty name]" NAME="Meyer-Schwickerath 1967" TYPE="JOURNAL_ARTICLE">
<AU>Meyer-Schwickerath G</AU>
<TI>Prophylaxis and giant tear</TI>
<SO>Bibliotheca Ophthalmologica</SO>
<YR>1967</YR>
<VL>72</VL>
<PG>345-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2003" MODIFIED="2009-01-27 17:10:20 +0000" MODIFIED_BY=" Iris Gordon" NAME="Moore 2003" TYPE="JOURNAL_ARTICLE">
<AU>Moore JK, Scott IU, Flynn HW Jr, Smiddy WE, Murray TG, Kim JE, et al</AU>
<TI>Retinal detachment in eyes undergoing pars plana vitrectomy for removal of retained lens fragments</TI>
<SO>Ophthalmology</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>4</NO>
<PG>709-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navarro-2005" MODIFIED="2009-01-28 09:58:59 +0000" MODIFIED_BY=" Iris Gordon" NAME="Navarro 2005" TYPE="JOURNAL_ARTICLE">
<AU>Navarro R, Gris O, Broc L, Corcostegui B</AU>
<TI>Bilateral giant retinal tear following posterior chamber phakic intraocular lens implantation</TI>
<SO>Journal of Refractive Surgery</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>3</NO>
<PG>298-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ozdamar-1998" MODIFIED="2009-01-28 09:59:54 +0000" MODIFIED_BY=" Iris Gordon" NAME="Ozdamar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ozdamar A, Aras C, Sener B, Oncel M, Karacorlu M</AU>
<TI>Bilateral retinal detachment associated with giant retinal tear after laser-assisted in situ keratomileusis</TI>
<SO>Retina</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>176-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pal-2005" MODIFIED="2009-02-12 21:36:47 +0000" MODIFIED_BY="[Empty name]" NAME="Pal 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pal N, Sharma YR, Azad R, Chandra P</AU>
<TI>Isolated bilateral microspherophakia with giant retinal tear and rhegmatogenous retinal detachment</TI>
<SO>Journal of Pediatric Ophthalmology and Strabismus</SO>
<YR>2005</YR>
<VL>42</VL>
<NO>4</NO>
<PG>238-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pollack-1994" MODIFIED="2009-01-28 10:01:57 +0000" MODIFIED_BY=" Iris Gordon" NAME="Pollack 1994" TYPE="JOURNAL_ARTICLE">
<AU>Pollack A, Milstein A, Oliver M, Zalish M</AU>
<TI>Circumferential argon laser photocoagulation for prevention of retinal detachment</TI>
<SO>Eye</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>Pt 4</NO>
<PG>419-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pournaras-2006" MODIFIED="2011-12-12 14:30:11 +0000" MODIFIED_BY=" Iris Gordon" NAME="Pournaras 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pournaras JA, Laffitte E, Guex-Crosier Y</AU>
<TI>Bilateral giant retinal tear and retinal detachment in a young emmetropic man after Jarish-Herxheimer reaction in ocular syphilis</TI>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>2006</YR>
<VL>223</VL>
<NO>5</NO>
<PG>447-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-2011" MODIFIED="2011-12-12 14:15:51 +0000" MODIFIED_BY="Anupa Shah" NAME="Review Manager 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizzo-2003" MODIFIED="2009-01-28 10:04:09 +0000" MODIFIED_BY=" Iris Gordon" NAME="Rizzo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rizzo S, Belting C, Genovesi-Ebert F</AU>
<TI>Two cases of giant retinal tear after implantation of a phakic intraocular lens</TI>
<SO>Retina</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>411-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robertson-1979" MODIFIED="2009-01-28 10:07:45 +0000" MODIFIED_BY=" Iris Gordon" NAME="Robertson 1979" TYPE="JOURNAL_ARTICLE">
<AU>Robertson DM, Priluck IA</AU>
<TI>360 degrees prophylactic cryoretinopexy. A clinical and experimental study</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1979</YR>
<VL>97</VL>
<NO>11</NO>
<PG>2130-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rofail-2005" MODIFIED="2009-01-28 10:08:27 +0000" MODIFIED_BY=" Iris Gordon" NAME="Rofail 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rofail M, Lee LR</AU>
<TI>Perfluoro-n-octane as a postoperative vitreoretinal tamponade in the management of giant retinal tears</TI>
<SO>Retina</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>7</NO>
<PG>897-901</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schepens-1962" MODIFIED="2008-11-01 12:17:41 +0000" MODIFIED_BY="[Empty name]" NAME="Schepens 1962" TYPE="JOURNAL_ARTICLE">
<AU>Schepens CL, Dobble JG, McMeel JW</AU>
<TI>Retinal detachments with giant breaks: preliminary report</TI>
<SO>Transactions - American Academy of Ophthalmology and Otolaryngology</SO>
<YR>1962</YR>
<VL>66</VL>
<PG>471-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schipper-2000" MODIFIED="2009-01-28 10:12:03 +0000" MODIFIED_BY=" Iris Gordon" NAME="Schipper 2000" TYPE="JOURNAL_ARTICLE">
<AU>Schipper I, Penn S</AU>
<TI>Giant retinal tears after photorefractive keratectomy</TI>
<SO>Retina</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>225-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-1975" MODIFIED="2009-01-18 21:58:59 +0000" MODIFIED_BY="[Empty name]" NAME="Scott 1975" TYPE="JOURNAL_ARTICLE">
<AU>Scott JD</AU>
<TI>Giant tear of the retina</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1975</YR>
<VL>95</VL>
<PG>142-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-1976" MODIFIED="2009-01-18 21:59:11 +0000" MODIFIED_BY="[Empty name]" NAME="Scott 1976" TYPE="JOURNAL_ARTICLE">
<AU>Scott JD</AU>
<TI>Equatorial giant tears affected by massive vitreous retraction</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1976</YR>
<VL>96</VL>
<PG>309-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-2002" MODIFIED="2009-01-28 10:12:56 +0000" MODIFIED_BY=" Iris Gordon" NAME="Scott 2002" TYPE="JOURNAL_ARTICLE">
<AU>Scott IU, Murray TG, Flynn HW Jr, Feuer WJ, Schiffman JC. Perfluoron Study Group</AU>
<TI>Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane</TI>
<SO>Ophthalmology</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>10</NO>
<PG>1828-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Topilow-1982" MODIFIED="2009-01-28 10:15:00 +0000" MODIFIED_BY=" Iris Gordon" NAME="Topilow 1982" TYPE="JOURNAL_ARTICLE">
<AU>Topilow HW, Nussbaum JJ, Freeman HM, Dickersin GR, Szyfelbein W</AU>
<TI>Bilateral acute retinal necrosis. Clinical and ultrastructural study</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1982</YR>
<VL>100</VL>
<NO>12</NO>
<PG>1901-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tseng-2004" MODIFIED="2009-01-28 10:17:01 +0000" MODIFIED_BY=" Iris Gordon" NAME="Tseng 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ</AU>
<TI>Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2004</YR>
<VL>137</VL>
<NO>6</NO>
<PG>1105-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vilaplana-1999" MODIFIED="2009-01-28 10:18:03 +0000" MODIFIED_BY=" Iris Gordon" NAME="Vilaplana 1999" TYPE="JOURNAL_ARTICLE">
<AU>Vilaplana D, Guinot A, Escoto R</AU>
<TI>Giant retinal tears after photorefractive keratectomy</TI>
<SO>Retina</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>4</NO>
<PG>342-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolfensberger-2003" MODIFIED="2009-01-28 10:21:56 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wolfensberger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wolfensberger TJ, Aylward GW, Leaver PK</AU>
<TI>Prophylactic 360° cryotherapy in fellow eyes of patients with spontaneous giant retinal tears</TI>
<SO>Ophthalmology</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>6</NO>
<PG>1175-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yam-2008" MODIFIED="2009-01-28 10:22:35 +0000" MODIFIED_BY=" Iris Gordon" NAME="Yam 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yam JC, Liu DT, Lee VY, Lam PT, Lam DS</AU>
<TI>Giant retinal tear after pneumatic retinopexy</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>2</NO>
<PG>232-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeung-2008" MODIFIED="2009-02-09 13:01:09 +0000" MODIFIED_BY="Anupa Shah" NAME="Yeung 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yeung L, Yang KJ, Chen TL, Wang NK, Chen YP, Ku WC, et al</AU>
<TI>Association between severity of vitreous haemorrhage and visual outcome in primary rhegmatogenous retinal detachment</TI>
<SO>Acta Ophthalmologica</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>2</NO>
<PG>165-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoshino-1989" MODIFIED="2009-01-28 10:25:33 +0000" MODIFIED_BY=" Iris Gordon" NAME="Yoshino 1989" TYPE="JOURNAL_ARTICLE">
<AU>Yoshino Y, Ideta H, Nagasaki H, Uemura A</AU>
<TI>Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy</TI>
<SO>Retina</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>2</NO>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-12-12 18:13:43 +0000" MODIFIED_BY="Anupa Shah">
<REFERENCE ID="REF-Lois-2009" MODIFIED="2011-12-12 18:13:43 +0000" MODIFIED_BY="Anupa Shah" NAME="Lois 2009" TYPE="COCHRANE_REVIEW">
<AU>Ang GS, Townend J, Lois N</AU>
<TI>Interventions for prevention of giant retinal tear in the fellow eye</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-12-12 18:13:42 +0000" MODIFIED_BY="Anupa Shah">
<IDENTIFIER MODIFIED="2011-12-12 18:13:42 +0000" MODIFIED_BY="Anupa Shah" TYPE="DOI" VALUE="10.1002/14651858.CD006909.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-11-27 16:09:11 +0000" MODIFIED_BY="Anupa Shah"/>
<ADDITIONAL_TABLES MODIFIED="2009-11-04 10:47:08 +0000" MODIFIED_BY="Anupa Shah">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-11-04 10:47:08 +0000" MODIFIED_BY="Anupa Shah" NO="1">
<TITLE MODIFIED="2008-11-27 16:09:11 +0000" MODIFIED_BY="Anupa Shah">Summary of case series assessing prophylactic 360-degree interventions of fellow eyes of patients with spontaneous unilateral giant retinal tear</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study name</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Methods</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Participants</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Intervention</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Follow</B> <B>up</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Outcomes</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-Al_x002d_Khairi-2008" TYPE="REFERENCE">Al-Khairi 2008</LINK>
</P>
</TD>
<TD>
<P>Retrospective</P>
</TD>
<TD>
<P>21 fellow eyes of 21 patients with spontaneous GRT</P>
</TD>
<TD>
<P>360-degree laser or cryotherapy</P>
</TD>
<TD>
<P>Mean 30 months</P>
</TD>
<TD>
<P>No case of GRT</P>
<P>1 case of RD (no data on time lag)</P>
<P>No data on complications</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-Freeman-1978" TYPE="REFERENCE">Freeman 1978</LINK>; <LINK REF="REF-Freeman-1979" TYPE="REFERENCE">Freeman 1979</LINK>
</P>
</TD>
<TD>
<P>Retrospective</P>
</TD>
<TD>
<P>55 fellow eyes of 55 patients with non-traumatic GRT</P>
</TD>
<TD>
<P>360-degree encircling scleral buckle or local cryotherapy</P>
</TD>
<TD>
<P>Mean 44 months</P>
</TD>
<TD>
<P>1 case of GRT at 36 months</P>
<P>1 case of RD at 5 months</P>
<P>1 transient vitreous haemorrhage</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Ghosh-2004" TYPE="REFERENCE">Ghosh 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Retrospective</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 fellow eyes of 18 patients with spontaneous GRT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>360-degree laser or cryotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean 28 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No case of GRT</P>
<P>No data on RD</P>
<P>No data on complications</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Glasspool-1973" TYPE="REFERENCE">Glasspool 1973</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Retrospective</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 fellow eyes of 3 patients with spontaneous GRT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>360-degree encircling scleral buckling combined with local cryotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean 18 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No case of GRT</P>
<P>No case of RD</P>
<P>No data on complications</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-Govan-1981" TYPE="REFERENCE">Govan 1981</LINK>
</P>
</TD>
<TD>
<P>Retrospective</P>
</TD>
<TD>
<P>106 eyes at 'high risk' of retinal detachment; includes 18 fellow eyes of 18 patients with GRT</P>
</TD>
<TD>
<P>360-degree cryotherapy</P>
</TD>
<TD>
<P>Mean 29 months</P>
</TD>
<TD>
<P>No case of GRT</P>
<P>3 cases of RD at 28, 36 and 54 months respectively</P>
<P>Complications in 14 (13.2%):<BR/>3 anterior uveitis, 3 cystoid macular oedema after cataract surgery, 2 transient loss of accommodation, 1 fixed dilated pupil, 2 cataract, 1 vitreous haemorrhage, 1 epiretinal membrane, 1 retinal haemorrhage, 1 choroidal haemorrhage</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-Wolfensberger-2003" TYPE="REFERENCE">Wolfensberger 2003</LINK>
</P>
</TD>
<TD>
<P>Retrospective</P>
</TD>
<TD>
<P>48 fellow eyes of 48 patients with spontaneous GRT</P>
</TD>
<TD>
<P>360-degree cryotherapy</P>
</TD>
<TD>
<P>Mean 84 months</P>
</TD>
<TD>
<P>1 case of GRT at 6 months</P>
<P>2 cases of RD at 6 and 11 months respectively</P>
<P>No complications</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRT: giant retinal tear<BR/>RD: retinal detachment not due to giant retinal tear</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-12-12 15:01:15 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-12-12 13:57:32 +0000" MODIFIED_BY="Anupa Shah" NO="1">
<TITLE MODIFIED="2008-08-06 11:41:53 +0100" MODIFIED_BY="Anupa Shah">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-12 13:57:32 +0000" MODIFIED_BY="Anupa Shah">
<P>#1 MeSH descriptor Retinal Perforations<BR/>#2 MeSH descriptor Retinal Detachment<BR/>#3 giant near retin* near tear*<BR/>#4 retin* near break*<BR/>#5 retin* near tear*<BR/>#6 retin* near detach*<BR/>#7 retin* near perforat*<BR/>#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)<BR/>#9 MeSH descriptor Scleral Buckling<BR/>#10 scleral near buckl*<BR/>#11 scleral near encircl*<BR/>#12 encircling band<BR/>#13 MeSH descriptor Cryotherapy<BR/>#14 cryotherap*<BR/>#15 MeSH descriptor Light Coagulation<BR/>#16 laser* near photocoagulat*<BR/>#17 (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)<BR/>#18 prophyla*<BR/>#19 prevent*<BR/>#20 ameliorate*<BR/>#21 (#18 OR #19 OR #20)<BR/>#22 (#8 AND #17)<BR/>#23 (#21 AND #22)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-12-12 15:01:15 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-08-06 11:43:37 +0100" MODIFIED_BY="Anupa Shah">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-12 15:01:15 +0000" MODIFIED_BY="[Empty name]">
<P>1. randomized controlled trial.pt.<BR/>2. (randomized or randomised).ab,ti.<BR/>3. placebo.ab,ti.<BR/>4. dt.fs.<BR/>5. randomly.ab,ti.<BR/>6. trial.ab,ti.<BR/>7. groups.ab,ti.<BR/>8. or/1-7<BR/>9. exp animals/<BR/>10. exp humans/<BR/>11. 9 not (9 and 10)<BR/>12. 8 not 11<BR/>13. case-control studies/<BR/>14. (case adj2 control$).tw.<BR/>15. or/13-14<BR/>16. 12 or 15<BR/>17. retinal perforations/<BR/>18. retinal detachment/<BR/>19. (giant adj2 retina$ adj2 tear$).tw.<BR/>20. (retina$ adj2 break$).tw.<BR/>21. (retina$ adj2 tear$).tw.<BR/>22. (retina$ adj2 detach$).tw.<BR/>23. (retina$ adj2 perforat$).tw.<BR/>24. or/17-23<BR/>25. scleral buckling/<BR/>26. (scleral adj2 buckl$).tw.<BR/>27. (scleral adj2 encircl$).tw.<BR/>28. encircling band.tw.<BR/>29. exp cryotherapy/<BR/>30. cryotherap$.tw.<BR/>31. exp light coagulation/<BR/>32. (laser adj2 photocoagulat$).tw.<BR/>33. or/25-32<BR/>34. 24 and 33<BR/>35. prophyla$.tw.<BR/>36. prevent$.tw.<BR/>37. ameliorate$.tw.<BR/>38. or/35-37<BR/>39. 34 and 38<BR/>40. 16 and 39<BR/>
</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-12-12 14:03:02 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-08-06 11:43:48 +0100" MODIFIED_BY="Anupa Shah">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-12 14:03:02 +0000" MODIFIED_BY="[Empty name]">
<P>1. exp randomized controlled trial/<BR/>2. exp randomization/<BR/>3. exp double blind procedure/<BR/>4. exp single blind procedure/<BR/>5. random$.tw.<BR/>6. or/1-5<BR/>7. (animal or animal experiment).sh.<BR/>8. human.sh.<BR/>9. 7 and 8<BR/>10. 7 not 9<BR/>11. 6 not 10<BR/>12. exp clinical trial/<BR/>13. (clin$ adj3 trial$).tw.<BR/>14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>15. exp placebo/<BR/>16. placebo$.tw.<BR/>17. random$.tw.<BR/>18. exp experimental design/<BR/>19. exp crossover procedure/<BR/>20. exp control group/<BR/>21. exp latin square design/<BR/>22. or/12-21<BR/>23. 22 not 10<BR/>24. 23 not 11<BR/>25. exp comparative study/<BR/>26. exp evaluation/<BR/>27. exp prospective study/<BR/>28. (control$ or prospectiv$ or volunteer$).tw.<BR/>29. or/25-28<BR/>30. 29 not 10<BR/>31. 30 not (11 or 23)<BR/>32. 11 or 24 or 31<BR/>33. case control study/<BR/>34. (case$ adj2 control$).tw.<BR/>35. or/33-34<BR/>36. 32 or 35<BR/>37. retina tear/<BR/>38. exp retina detachment/<BR/>39. (giant adj2 retina$ adj2 tear$).tw.<BR/>40. (retina$ adj2 break$).tw.<BR/>41. (retina$ adj2 tear$).tw.<BR/>42. (retina$ adj2 detach$).tw.<BR/>43. (retina$ adj2 perforat$).tw.<BR/>44. or/37-43<BR/>45. sclera buckling procedure/<BR/>46. (scleral adj2 buckl$).tw.<BR/>47. (scleral adj2 encircl$).tw.<BR/>48. encircling band.tw.<BR/>49. exp cryotherapy/<BR/>50. cryotherap$.tw.<BR/>51. exp laser coagulation/<BR/>52. (laser adj2 photocoagulat$).tw.<BR/>53. or/45-52<BR/>54. prophyla$.tw.<BR/>55. prevent$.tw.<BR/>56. ameliorate$.tw.<BR/>57. or/54-56<BR/>58. 44 and 53 and 57<BR/>59. 36 and 58<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-08-06 11:44:14 +0100" MODIFIED_BY="Anupa Shah" NO="4">
<TITLE MODIFIED="2008-08-06 11:43:58 +0100" MODIFIED_BY="Anupa Shah">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-06 11:44:14 +0100" MODIFIED_BY="Anupa Shah">
<P>retina$ and break$ or tear$ or detach$ or perforat$ and proph$ or prevent$ or ameliorate$</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-12-12 14:03:38 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-12-12 13:42:24 +0000" MODIFIED_BY="[Empty name]">
<I>meta</I>Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-12 14:03:38 +0000" MODIFIED_BY="[Empty name]">
<P>giant retinal tear</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2011-12-12 14:04:42 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-12-12 13:42:42 +0000" MODIFIED_BY="[Empty name]">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-12 14:04:42 +0000" MODIFIED_BY="[Empty name]">
<P>(Prophylactic OR Prevent OR Ameliorate) AND (Giant Retinal Tear)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2011-12-12 14:05:13 +0000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2011-12-12 13:42:59 +0000" MODIFIED_BY="[Empty name]">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-12 14:05:13 +0000" MODIFIED_BY="[Empty name]">
<P>Giant Retinal Tear</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>